MotherToBaby

Medications and More during pregnancy and breastfeeding

Buscar

866.626.6847

Natalizumab

Selected References:

  • Andersen, J. B, et al. 2023. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis. European journal of neurology, 30(1), 162–171.
  • Ciplea, A. I, et al. 2020. Exposure to natalizumab during pregnancy and lactation is safe – Commentary. Multiple sclerosis (Houndmills, Basingstoke, England), 26(8), 892–893.
  • D’Amico, E, et al. 2021. Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. Multiple sclerosis (Houndmills, Basingstoke, England), 27(14), 2284–2287.
  • Ebrahimi N, et al. 2014. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015 Feb;21(2):198-205.
  • Friend S, et al. 2016. Evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. Aug 24;16(1):150
  • Gklinos, P, et al. 2023. Monoclonal Antibodies in Pregnancy and Breastfeeding in Patients with Multiple Sclerosis: A Review and an Updated Clinical Guide.Pharmaceuticals (Basel, Switzerland),16(5), 770.
  • Haghikia A, , et al. 2014. Natalizumab use during the third trimester of pregnancy. JAMA Neurol 71(7): 891-895.
  • Mahadevan U, , et al. 2019. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. Apr;156(5):1508-1524.
  • Massarotti, C., et al. 2021. Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research. Journal of clinical medicine, 10(22), 5401
  • O’Leary, S, et al. 2023. Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis. Journal of infusion nursing : the official publication of the Infusion Nurses Society, 46(6), 347–359.
  • Oreja-Guevara, C, et al. 2023. Family Planning in Fertile-Age Patients With Multiple Sclerosis (MS) (ConPlanEM Study): Delphi Consensus Statements. Cureus, 15(8), e44056
  • Peng A, et al. 2018. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review. J Neurol Sci. 2019 Jan 15;396:202-205.
  • Portaccio E, et al. 2018. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. I: Fetal risks. Neurology. Page #s or journal volume?
  • Simone, I. L, et al. 2021. Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies.Frontiers in neurology,12, 697974.
  • Tysabri. Drug Approval Package. Pharmacology reviews. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125104s000_natalizumab.cfm
  • Ramesh, V, et al. 2022. Adverse Obstetric Outcomes in Pregnant Women Using Natalizumab for the Treatment of Multiple Sclerosis: A Systematic Review. Cureus,14(10), e29952

MotherToBaby cuenta con el apoyo de la Administración de Recursos y Servicios de Salud (HRSA) del Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS) como parte de una adjudicación por un total de $6,000,000 con cero porcentaje financiado con fuentes no gubernamentales. Los contenidos son los del autor/es y no representan necesariamente los puntos de vista oficiales de, ni un respaldo, por HRSA, HHS o el Gobierno de los Estados Unidos.